glp-1 medications in weight management Now Recommended First for Loss: What Heart Patients Should Know What to Make of the
Description
Conflicts of interest The authors have no conflicts of interest to disclose
Its a pragmatic approach, if a bit idealistic
2016, Harlan-Teklad)
Stateline is part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity
Results : Our NMA of 29 RCTs with 145,895 participants found that only two exendin-4 derivativeslixisenatide and high-dose efpeglenatide (i.e., 6 mg/week)showed increased hearing loss events compared to controls
